U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07123519) titled 'A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases' on Aug. 08.
Brief Summary: This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc. Aproximately 18 patients aged 18-65 will receive a single infusion of YTS109 cells. The dose groups are set to commence at 3E6 STAR -T cells/kg, employing a 3+3 escalation principle for dose titration. The primary objective of this study is to evaluate the safety of YTS109 cells therapy in treating recurrent/refractory a...